Financhill
Sell
43

CUE Quote, Financials, Valuation and Earnings

Last price:
$0.84
Seasonality move :
-7.68%
Day range:
$0.70 - $1.03
52-week range:
$0.45 - $1.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.70x
P/B ratio:
9.80x
Volume:
6.3M
Avg. volume:
466.3K
1-year change:
-8.15%
Market cap:
$64.5M
Revenue:
$9.3M
EPS (TTM):
-$0.67

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CUE
Cue Biopharma
$2M -$0.13 -39.92% -35% $4.00
ATNM
Actinium Pharmaceuticals
-- -$0.35 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$0.47 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CUE
Cue Biopharma
$0.86 $4.00 $64.5M -- $0.00 0% 6.70x
ATNM
Actinium Pharmaceuticals
$1.59 $5.00 $49.6M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.65 $0.85 $3.8M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.60 -- $25.7M -- $0.00 0% --
OGEN
Oragenics
$1.42 $1.00 $1M -- $0.00 0% 0.45x
TOVX
Theriva Biologics
$0.47 $7.00 $3.8M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CUE
Cue Biopharma
33.9% -0.546 5.99% 0.85x
ATNM
Actinium Pharmaceuticals
-- -3.037 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
NNVC
Nanoviricides
-- -0.318 -- --
OGEN
Oragenics
-- 0.068 -- --
TOVX
Theriva Biologics
-- -3.388 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CUE
Cue Biopharma
-- -$12.3M -159.08% -200.7% -2881% -$8.3M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
NNVC
Nanoviricides
-- -$2.2M -- -- -- -$2M
OGEN
Oragenics
-- -$2M -- -- -- -$2.1M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

Cue Biopharma vs. Competitors

  • Which has Higher Returns CUE or ATNM?

    Actinium Pharmaceuticals has a net margin of -2911.4% compared to Cue Biopharma's net margin of -11511.11%. Cue Biopharma's return on equity of -200.7% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    CUE
    Cue Biopharma
    -- -$0.17 $10M
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About CUE or ATNM?

    Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 367.29%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 214.47%. Given that Cue Biopharma has higher upside potential than Actinium Pharmaceuticals, analysts believe Cue Biopharma is more attractive than Actinium Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CUE
    Cue Biopharma
    1 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is CUE or ATNM More Risky?

    Cue Biopharma has a beta of 1.433, which suggesting that the stock is 43.294% more volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.

  • Which is a Better Dividend Stock CUE or ATNM?

    Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CUE or ATNM?

    Cue Biopharma quarterly revenues are $421K, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Cue Biopharma's net income of -$12.3M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 6.70x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CUE
    Cue Biopharma
    6.70x -- $421K -$12.3M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns CUE or NBY?

    NovaBay Pharmaceuticals has a net margin of -2911.4% compared to Cue Biopharma's net margin of -49.65%. Cue Biopharma's return on equity of -200.7% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    CUE
    Cue Biopharma
    -- -$0.17 $10M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About CUE or NBY?

    Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 367.29%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that Cue Biopharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe Cue Biopharma is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    CUE
    Cue Biopharma
    1 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is CUE or NBY More Risky?

    Cue Biopharma has a beta of 1.433, which suggesting that the stock is 43.294% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock CUE or NBY?

    Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CUE or NBY?

    Cue Biopharma quarterly revenues are $421K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Cue Biopharma's net income of -$12.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Cue Biopharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 6.70x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CUE
    Cue Biopharma
    6.70x -- $421K -$12.3M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns CUE or NNVC?

    Nanoviricides has a net margin of -2911.4% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -200.7% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CUE
    Cue Biopharma
    -- -$0.17 $10M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About CUE or NNVC?

    Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 367.29%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 306.25%. Given that Cue Biopharma has higher upside potential than Nanoviricides, analysts believe Cue Biopharma is more attractive than Nanoviricides.

    Company Buy Ratings Hold Ratings Sell Ratings
    CUE
    Cue Biopharma
    1 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is CUE or NNVC More Risky?

    Cue Biopharma has a beta of 1.433, which suggesting that the stock is 43.294% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

  • Which is a Better Dividend Stock CUE or NNVC?

    Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CUE or NNVC?

    Cue Biopharma quarterly revenues are $421K, which are larger than Nanoviricides quarterly revenues of --. Cue Biopharma's net income of -$12.3M is lower than Nanoviricides's net income of -$2.2M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 6.70x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CUE
    Cue Biopharma
    6.70x -- $421K -$12.3M
    NNVC
    Nanoviricides
    -- -- -- -$2.2M
  • Which has Higher Returns CUE or OGEN?

    Oragenics has a net margin of -2911.4% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -200.7% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CUE
    Cue Biopharma
    -- -$0.17 $10M
    OGEN
    Oragenics
    -- -$3.60 --
  • What do Analysts Say About CUE or OGEN?

    Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 367.29%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Cue Biopharma, analysts believe Oragenics is more attractive than Cue Biopharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    CUE
    Cue Biopharma
    1 0 0
    OGEN
    Oragenics
    0 1 0
  • Is CUE or OGEN More Risky?

    Cue Biopharma has a beta of 1.433, which suggesting that the stock is 43.294% more volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

  • Which is a Better Dividend Stock CUE or OGEN?

    Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CUE or OGEN?

    Cue Biopharma quarterly revenues are $421K, which are larger than Oragenics quarterly revenues of --. Cue Biopharma's net income of -$12.3M is lower than Oragenics's net income of -$2.2M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 6.70x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CUE
    Cue Biopharma
    6.70x -- $421K -$12.3M
    OGEN
    Oragenics
    0.45x -- -- -$2.2M
  • Which has Higher Returns CUE or TOVX?

    Theriva Biologics has a net margin of -2911.4% compared to Cue Biopharma's net margin of --. Cue Biopharma's return on equity of -200.7% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CUE
    Cue Biopharma
    -- -$0.17 $10M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About CUE or TOVX?

    Cue Biopharma has a consensus price target of $4.00, signalling upside risk potential of 367.29%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1402.15%. Given that Theriva Biologics has higher upside potential than Cue Biopharma, analysts believe Theriva Biologics is more attractive than Cue Biopharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    CUE
    Cue Biopharma
    1 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is CUE or TOVX More Risky?

    Cue Biopharma has a beta of 1.433, which suggesting that the stock is 43.294% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

  • Which is a Better Dividend Stock CUE or TOVX?

    Cue Biopharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CUE or TOVX?

    Cue Biopharma quarterly revenues are $421K, which are larger than Theriva Biologics quarterly revenues of --. Cue Biopharma's net income of -$12.3M is lower than Theriva Biologics's net income of -$4.3M. Notably, Cue Biopharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma is 6.70x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CUE
    Cue Biopharma
    6.70x -- $421K -$12.3M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock